According to a recent LinkedIn post from Truveta, new research conducted with SK Life Science, Inc. explores how seizure frequency data can be extracted from unstructured clinical notes at scale using the Truveta Language Model. The post references a Neurology study involving 2,480 patients treated with cenobamate, where the model reportedly identified seizure counts, frequency, and changes over time to build longitudinal patient timelines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that the model achieved a 97% high-confidence extraction rate across varied clinical note types, suggesting strong performance in handling real-world documentation. If this capability proves robust beyond the reported study, it could enhance Truveta’s value proposition in real-world evidence generation, potentially improving its competitive position in healthcare analytics and supporting future commercial partnerships or research collaborations.
By emphasizing the ability to unlock information embedded in clinical notes, the post suggests Truveta’s platform may enable larger-scale studies of treatment effectiveness and disease progression, particularly in complex conditions like epilepsy. For investors, such advancements in extracting structured insights from unstructured EHR data could translate into broader use cases, deeper integration with life science customers, and a stronger role in data-driven drug development and outcomes research.